thenewsfacts.com
  • Home
  • Latest News
  • Trending News
  • Technology
  • entertainment
  • Sports
  • Business
thenewsfacts.comthenewsfacts.com
Font ResizerAa
Search
  • Home
  • Latest News
  • Trending News
  • Technology
  • entertainment
  • Sports
  • Business
Follow US
© thenewsfacts : All Rights Reserved.

Home » India Recommends Bharat Biotech’s COVAXIN for Kids Under 12 Years

COVID Vaccines

India Recommends Bharat Biotech’s COVAXIN for Kids Under 12 Years

TheNewsFacts
Last updated: October 12, 2021 5:57 pm
TheNewsFacts
Share
India Recommends Bharat Biotech's COVID19 Vaccine for Kids
SHARE

Bharat Biotech’s COVID-19 vaccine for children under 12 years of age has got India’s Subject Expert Committee nod. This recommendations given by SEC today makes the first vaccine maker in the country to get such an approval after a review of its trial data for the 2-18 age-group.

The decision is a big bolster to India’s vaccination program to not only cover adults but also its younger population. Most importantly, vaccinating children against the coronavirus, having already rolled out more than 950 million doses to adults among its population of nearly 1.4 billion.

Bharat Biotech‘s Covaxin, which uses an inactivated coronavirus with an immunity booster, is among the three shots that are being used in India as part of the vaccination drive for adults.

More than 110 million doses of Covaxin have been administered and the company is in the process of securing an emergency use listing from the World Health Organization, a decision that is expected later this month.

Bharat Biotech Covid 19 vaccine is the first in the world for age group from 2-18 years

COVAXIN
Covaxin for children under 12 year old gets India SEC recommendation

“This represents one of the first recommendations worldwide for COVID-19 vaccines for the 2-18 age group. Bharat Biotech sincerely thanks the DCGI, Subject Experts Committee, and CDSCO for their expedited review process. We now await further regulatory approvals from the CDSCO prior to product launch and market availability of Covaxin for children,” Bharat Biotech said in a statement.

Bharat Biotech has submitted data from clinical trials in the 2-18 years age group for Covaxin (BBV152) to CDSCO. The data has been thoroughly reviewed by the CDSCO and SEC and have provided their positive recommendations, the vaccine maker said.

“After detailed deliberation, the committee recommended grant of market authorisation of the vaccine for the age group of 2 to 18 years for restricted use in emergency situations subject to the certain conditions,” the SEC recommendations stated.

The recommendations have been forwarded to the Drugs Controller General of India (DCGI) for final approval.

TAGGED:BHARAT BIOTECH COVAXINCovaxinCovaxin for Kids
Share This Article
Email Copy Link Print
Previous Article 5 Reasons why the world loves Neymar? 5 reasons why the world can’t stop loving Neymar?
Next Article Now, 111 Million Fans Play Squid Game, With No More Prank Calls Now, 111 Million Fans Play Squid Game, With No More Prank Calls

Your Trusted Source for Accurate and Timely Updates!

We're committed to providing accurate and unbiased news as it unfolds, earning the trust of a large audience. Stay informed with our news updates on the latest events and trends, keeping you ahead of the curve.
FacebookLike
XFollow
InstagramFollow

Popular Posts

Beyond Borders: The Untold Importance of International Mother Language Day 2023

International Mother Language Day 2023 celebrated today marks great relevance now, as we find ourselves…

By
TheNewsFacts

Paris 2024: A Mesmerizing Hue, The Debut of the Purple Track

August 2, 2024: The world today witnessed a Mesmerizing Hue: The Debut of the Purple…

By
TheNewsFacts

COVID-19 : India Issues New International Arrivals Guidelines

Come February 14, international arrivals to India gets a big relief. Under the new guidelines…

By
TheNewsFacts

You Might Also Like

Big News of the Day: India's COVAXIN Gets Regular Market Approval from DCGI
COVID Vaccines

India’s COVAXIN Gets Regular Market Approval

By
TheNewsFacts
Intra Nasal Vaccines May be the Best way to Prevent Long Term Infections - Experts
COVID Vaccines

Intra Nasal Vaccines May be the Best way to Prevent Long Term Infections – Scientist

By
TheNewsFacts
Pfizer's Omicron-targeted Vaccine Trial Begins
COVID Vaccines

Pfizer’s Omicron targeted Vaccine Trial Begins

By
TheNewsFacts
Difference between Covishield and Covaxin (new update)
COVID Vaccines

Difference between Covishield and Covaxin (new update)

By
TheNewsFacts
thenewsfacts thenewsfacts

About US


TheNewsFacts: Brings you the interesting facts, news facts and updates from India an the world across politics, tech, entertainment, business, tending, and more. We deliver what you love to read.
Top Categories
  • Latest News
  • Trending News
  • Paris Olympics 2024
  • Sports
  • Entertainment
  • Business
  • Technology
Usefull Links
  • About The News Facts
  • Latest News
  • Privacy Policy
  • Editorial Policy
  • Disclaimer
  • Contact Us
Follow us
Facebook Twitter Instagram

© thenewsfacts. All Rights Reserved.

Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?